Autolus Therapeutics plc AUTL was a big mover last session, as the company saw its shares rise nearly 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $24.30–$31.47 in the past one-month time frame, witnessed a sharp increase yesterday.

The company has seen one positive estimate revision in the past few weeks, while its Zacks Consensus Estimate for the current quarter has also moved higher over the past few weeks, suggesting that more solid trading could be ahead for Autolus Therapeutics. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.

Autolus Therapeutics currently has a Zacks Rank #3 (Hold) while its Earnings ESP is positive.

Autolus Therapeutics PLC Sponsored ADR Price

Autolus Therapeutics PLC Sponsored ADR Price | Autolus Therapeutics PLC Sponsored ADR Quote

Investors interested in the Medical - Biomedical and Genetics industry may consider a better-ranked stock like Celcuity, Inc. CELC, which carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Is AUTL going up? Or down? Predict to see what others think:Up or Down

Radical New Technology Creates $12.3 Trillion Opportunity

Imagine buying Microsoft stock in the early days of personal computers… or Motorola after it released the world’s first cell phone. These technologies changed our lives and created massive profits for investors.

Today, we’re on the brink of the next quantum leap in technology. 7 innovative companies are leading this “4th Industrial Revolution” - and early investors stand to earn the biggest profits.

See the 7 breakthrough stocks now>>

Click to get this free report

Autolus Therapeutics PLC Sponsored ADR (AUTL): Free Stock Analysis Report

Celcuity, Inc. (CELC): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.